金银花口服液治疗新型冠状病毒肺炎80例临床疗效分析

目的探讨金银花口服液治疗新型冠状病毒肺炎(简称新冠肺炎,COVID-19)的临床疗效。方法将120例COVID-19普通型患者按照1∶2随机分为两组。对照组40例,仅给予洛匹那韦/利托那韦或阿比朵尔、α-干扰素等常规治疗;治疗组80例,在常规治疗的基础上加用金银花口服液治疗。比较两组患者治疗前(V1)和治疗5 d(V2)、10 d(V3)的临床症状消失率、呼吸道样本新型冠状病毒(SARS-CoV-2)-qRT-PCR转阴率、胸部CT检查影像学评分及不良反应发生率。结果两组患者基线资料比较,差异无统计学意义。与对照组治疗后比较,治疗组V2时临床发热(77.94%比56.67%)、乏力(75.86%比57.14%)、咳嗽(67.74%比45.83%)消失率明显提高(P<0.05),治疗组V3时临床咳嗽消失率(90.32%比66.67%)明显提高(P<0.05),治疗组V3时胸部CT检查影像学评分(10.95±1.43)分比(12.92±2.02)分]明显降低(P<0.01);治疗组临床发热、乏力消失率V3时(100%比100%,91.38%比85.71%),SARS-CoV-2-qRT-PCR转阴率V2时(81.25%比77.50%)与V3时(93.75%比92.50%),以及胸部CT检查影像学评分V2时(15.09±2.56)分比(15.12±3.371)分]的差异无统计学意义(P>0.05),但显示出有改善趋势。治疗组和对照组与用药相关的不良反应发生率分别为1.25%和0,差异无统计学意义(P>0.05)。结论在常规治疗基础上加用金银花口服液,可以显著改善新冠肺炎患者的发热、乏力、咳嗽症状,减轻肺部病变,对病毒核酸检测转阴也显示出良好的改善趋势。

Clinical Efficacy of Jinyinhua Oral Liquid in the Treatment of 80 Patients with Coronavirus Disease 2019

Objective To investigate the clinical efficacy of Jinyinhua Oral Liquid in the treatment of coronavirus disease 2019(COVID-19).Methods Totally 120 patients with common type of COVID-19 were randomly divided into two groups according to 1∶2.Totally 40 patients in the control group were given routine treatment such as lopinavir/ritonavir,abidor orα-interferon,on this basis,80 patients in the observation group were treated with Jinyinhua Oral Liquid.Before treatment(V1),after 5 d(V2)and 10 d(V3)of treatment,the disappearance rate of clinical symptoms,the negative rate of severe acute respiratory syndrome coronavirus 2(SARS-CoV-2)-qRT-PCR of the upper respiratory tract samples,the score of chest CT image and the incidence of adverse reactions were compared between the two groups.Results There was no significant difference in baseline data between the two groups(P<0.05).Compared with the control group after treatment,t he disappearance rate of fever(77.94%vs.56.67%),fatigue(75.86%vs.57.14%)and cough(67.74%vs.45.83%)were significantly increased in the treatment group at V2 and the disappearance rate of cough(90.32%vs.66.67%)was significantly increased in the treatment group at V3(P<0.05),the score of chest CT image in the treatment group at V3 was significantly lower(10.95±1.43)points vs.(12.92±2.02)points,P<0.01].Compared with those in the control group,there was no significant difference in the disappearance rate of fever and fatigue(100%vs.100%,91.38%vs.85.71%)in the treatment group at V2,the negative rates of SARS-CoV-2-qRT-PCR in the treatment group at V2(81.25%vs.77.50%)and at V3(93.75%vs.92.50%),and the chest CT imaging score(15.09±2.56)points vs.(15.12±3.371)points]in the treatment group at V2(P>0.05),but showed an improvement trend.The incidence of drug-related adverse reactions was 1.25%in the treatment group and 0 in the control group,which had no significant difference(P>0.05).Conclusion Jinyinhua Oral Liquid combined with routine treatment can significantly improve the symptoms such as fever,fatigue and cough of patients,reduce lung lesions,and show a good trend to improve the negative rate of nucleic acid testing.